GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY

Italian clinical research in non-small-cell lung cancer

ABSTRACT Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15–20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC p…

Terapia di seconda linea del carcinoma gastrico avanzato con la combinazione Irinotecan (Cpt 11) + Mitomicina (MMc). Studio di fase II del Gruppo Oncologico dell’Italia Meridionale (prot. GOIM 2106) VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004

Mitoxantrone + Prednisone versus Taxotere + Prednisone nel trattamento del carcinoma prostatico ormonorefrattario (cpor ). Studio randomizzato di fase II del Gruppo Oncologico dell’Italia Meridionale (GOIM ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale